A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEF.

In 30 seconds

This phase I randomized controlled trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ulacamten, a cardiac myosin inhibitor, in healthy adults. The study found that ulacamten demonstrated dose-proportional exposure and a predictable pharmacokinetic/pharmacodynamic relationship with changes in systolic function measures, with all adverse events being mild or moderate in severity.

Key findings

• Ulacamten showed a median plasma half-life of 14-18 hours and median t max of 1.5-5 hours.
• Mean accumulation of exposure at steady state was 37-69%, consistent with the half-life.
• All adverse events reported were mild or moderate in severity.

Why it matters

Understanding the safety and pharmacokinetics of ulacamten is crucial for its potential use in treating heart failure with preserved ejection fraction, a condition with limited treatment options.